India, Aug. 25 -- Biodesix, Inc. (BDSX), a diagnostic solutions company focused on lung disease, touched a new 52-week high of $29.18 in today's trading. The stock has surged over 90% over the past three months, reflecting increased investor interest.
The company reported financial results for the second quarter ended June 30, 2026, earlier this month.
Revenue was $26.9 million for the second quarter of 2026, a sharp increase from $20.1 million in the same quarter of 2025.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....